4Monem AS, Ali FM, Ismail MW. Prolonged effect of liposomes encapsulating pilocarpine HCL in normal and glaucomatous rabbit. Int J Pharm, 2000, 198(1):29-38.
5Assil KK, Weinreb RN. Multivesicular llposomes sustained release of the antimetabolite cytarabine in the eye. Arch Ophthamol, 1987, 105(3):400-403.
6Smolin G, Okumoto M, Feiler S, et al. Idoxuridine-liposome therapy for herpes simplex keratitis. Am J Ophthalmol,1981, 91(2):220-225.
7Fresta M, Fontana G, Bucolo C, et al. Ocular tolerability and in vivo bioavailability of poly (ethylene glycol) (PEG)-coated polyethyl-2-cyanoacrylate nanosphere-encapsulated acyclovir[ J ]. J Pharm Sci, 2001,90 ( 3 ) : 288 - 297.
8Seth AK, Misra A. Mathematical modelling of preparation of acyclovir liposomes: reverse phase evaporation method [ J ]. J Pharm Pharm Sci, 2002,5 ( 3 ) : 285 - 291.
9Ritger PL, Peppas NA. A simple equation for description of solute release I. Fickian and non-Fickian release from non-swellable devices in the form of slabs, spheres, cylinders or discs [ J ]. J Control Release, 1987,5( 1 ) :23 - 36.
10Yuan J. Estimation of variation for AUC in animal studies [ J ]. J Pharm Sci, 1993,82 ( 7 ) :761 - 763.
